Faculty Presenters

Jill Burke, APRN, BC dipACLM

Hematology/Oncology Nurse Practitioner
Massachusetts General Hospital
Boston, MA

Jill Burke has spent the last 35 years at Massachusetts General Hospital, with the first 12 years as inpatient hematology/oncology staff nurse, and the last 23 years at a nurse practitioner. Jill’s focus of care has been multiple myeloma for 15 years. She presently works in the outpatient setting, managing patients with plasma cell diseases throughout diagnosis and treatment.She is a strong patient advocate, ensuring that patients reach their optimal level of functioning and enjoy life. She is known for explaining to newly diagnosed patients that she hopes their diagnosis will occupy a small sliver in the pie of their life.

Jill is certified by the American College of Lifestyle Medicine as a lifestyle coach, and she is in the process of organizing lifestyle medicine clinics for patients diagnosed with monoclonal gammopathy of unknown significance, multiple myeloma, and post CAR-T. Jill has given talks and presented posters both nationally and internationally.

Diana Cirstea, MD

Medical Oncologist 
Massachusetts General Hospital
Boston, MA

Diana Cirstea, MD, is a hematologist-oncologist at the Mass General Brigham Cancer Center, specializing in plasma cell disorders with a focus on T-cell redirecting therapies, including CAR T cells and T-cell engagers. She completed a Postdoctoral Research Fellowship at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, followed by a Hematology/Oncology Fellowship at Boston Medical Center. Before joining Massachusetts General Hospital, she spent over two years as a Bone Marrow Transplant and CAR T hospitalist at Dana-Farber and Brigham and Women’s Hospital. 

At Massachusetts General Hospital, Dr. Cirstea is part of the Multiple Myeloma Program, serves as a faculty member at Harvard Medical School, and is the Principal Investigator of the BOSS (Bispecific Outpatient Safe Step-up) program, which developed and implemented an outpatient strategy for the safe administration of
bispecific antibody step-up dosing. Her work is dedicated to advancing innovative immune-based treatments and expanding patient access to novel therapies.

E. Bridgett Kim, PharmD, BCPS, BCOP

Clinical Pharmacy Specialist 
Multiple Myeloma 
Massachusetts General Hospital
Boston, MA

E. Bridget Kim, PharmD, BCPS, BCOP is a Clinical Pharmacy Specialist in Multiple Myeloma at Massachusetts General Hospital. She received her PharmD degree from the University of North Carolina at Chapel Hill School of Pharmacy, followed by PGY-1 training at Boston Medical Center, and board certifications in pharmacotherapy (BCPS) and oncology (BCOP). 

Her publications include original research papers and review articles in peer-reviewed journals and poster/platform presentations at national and international meetings. Currently, she serves in Pharmacy & Therapeutics Safety Committee - oncology subcommittee and Pharmacy Medication Safety Committee at MGH. She is also a preceptor for PGY-1 and PGY-2 pharmacy residents and pharmacy students. Her research interests include topics in Multiple Myeloma, patient quality initiatives, and supportive care.

Robert Friedman, MD

Hematologist Oncologist 
Dana Farber Cancer Institute
Boston, MA

Program Planning Committee

Jesus G. Berdeja, M.D. (Content Co-Chair)

Director of Multiple Myeloma Research
The Greco-Hainsworth Tennessee Oncology Centers for Research
Nashville, TN

Jesus G. Berdeja received his undergraduate degree from Stanford University and medical degree from Harvard University. He completed his internship and residency in the Department of Internal Medicine at the University of California in San Francisco and fellowships in medical oncology and hematology at Johns Hopkins University School of Medicine in Baltimore.

Dr. Berdeja specializes in clinical hematology, with a focus on multiple myeloma. Additionally, he is an active member of several professional organizations, including the International Myeloma Society, the American Society of Clinical Oncology, the American Society of Hematology, the International Myeloma Working Group and the Clinical Trials Myeloma Intergroup Committee. An active researcher, Dr. Berdeja has been the principal investigator many funded clinical trials in the field of multiple myeloma. He has published extensively in the peer-reviewed literature and is a frequent invited lecturer.

Charise Gleason, MSN, NP-BC, AOCNP (Content Co-Chair)

VP and Chief APP Officer
Adjunct Faculty,
Nell Hodgson Woodruff School of Nursing
Emory Healthcare
Atlanta, GA

Charise Gleason, MSN, NP-BC, AOCNP®, is the VP and Chief Advanced Practice Officer for Emory Healthcare and adjunct faculty at the Nell Hodgson Woodruff School of Nursing at Emory University. She has been a nurse practitioner in the Multiple Myeloma program at the Winship Cancer Institute of Emory University for over twenty years. She earned both her bachelor’s and master’s degrees from Emory University and holds an advanced oncology certification through the ONCC. Ms. Gleason has been an active presenter and educator on the topics of multiple myeloma and has authored or co-authored many publications, including book chapters, abstracts, articles for nursing journals, and scientific publications.

Disclosures:

Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Other Contributors

All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.

Charise Gleason, MSN, NP-C, AOCNP discloses no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months.

Jesús G. Berdeja, M.D. discloses contracted research with 2 Seventy Bio, Abbvie, Amgen, BMS, C4 Therapeutics, Caribou Biosciences, CARsgen, Cartesian Therapeutics, Celularity, CRISPR Therapeutics, Fate Therapeutics, Genentech, GSK, Ichnos Sciences, Incyte, Janssen, Juno Therapeutics, K36 Therapeutics. Karyopharm, Lilly, Novartis, Poseida, Roche, Sanofi, Takeda, Consulting Fee's with AstraZeneca, BMS, Caribou Biosciences, Galapagos, Janssen, K36 Therapeutics, Kite Pharma, Legend Biotech, Pfizer, Regeneron, Roche, Sanofi, Sebia, Takeda and Speaker's Honoraria with Janssen during the past 24 months.